Published On: Wed, Dec 18th, 2013

Teva Settles Viagra Patent Litigation With Pfizer


Teva says it will be able to launch generic Viagra in the US in 2017.

viagra teva law

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that its subsidiary Teva Pharmaceuticals USA, Inc. has entered into an agreement with Pfizer Inc. to settle patent litigation related to Teva’s generic version of Pfizer’s Viagra (sildenafil citrate) tablets.

Under the terms of the agreement Teva will be able to launch its Abbreviated New Drug Application (ANDA) products pursuant to a royalty-bearing license on December 11, 2017, or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential.

The U.S. Food and Drug Administration (FDA) has already granted tentative approval for Teva’s generic version of Pfizer’s Viagra (sildenafil citrate) tablets, 25, 50, and 100 mg.

Viagra had annual sales of approximately $1.2 billion in the United States, based on IMS sales data as of September 2013.

Read more about: , , , , , , , ,

Wordpress site Developed by Fixing WordPress Problems